A New Treatment Strategy that Reduces Growth/Differentiation Factor-15 in Type-2 Diabetes Mellitus: Major Autohemotherapy: A Pilot Study
Growth/differentiation factor-15 (GDF-15) is a diagnostic and prognostic marker associated with inflammation, renal damage, and cardiovascular risk in type-2 diabetes mellitus. Researchers have proposed treatment targets that reduce GDF-15 levels. Our aim in this study is to investigate the effect o...
Saved in:
Published in | Alternative therapies in health and medicine Vol. 29; no. 7; pp. 30 - 33 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
InnoVision Health Media, Inc
01.10.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Growth/differentiation factor-15 (GDF-15) is a diagnostic and prognostic marker associated with inflammation, renal damage, and cardiovascular risk in type-2 diabetes mellitus. Researchers have proposed treatment targets that reduce GDF-15 levels.
Our aim in this study is to investigate the effect of major autohemotherapy on GDF-15 levels and to evaluate it as a complementary therapy.
The research team designed a laboratory study to examine the effect of major hemotherapy on GDF-15 levels in patients with type-2 diabetes mellitus and healthy volunteers. Blood was drawn from the participants in a closed system, infused with ozone gas, and reinfused into the patients.
The study was carried out from 15 August-5 October at Kırşehir Training and Research Hospital Traditional and Complementary Medicine Center, Turkey.
The study was conducted prospectively, and two groups were formed, consisting of those with type-2 diabetes mellitus (n = 21) and healthy volunteers (n = 14).
All participants received 10 sessions of major autohemotherapy at a concentration of 25-35 micrograms/milliliter twice a week. Before and after the application, GDF-15, fasting glucose, glycosylated hemoglobin, and lipid panel levels were studied and compared.
Age, GDF-15, fasting glucose, glycosylated hemoglobin, and triglyceride levels were found to be higher in the type-2 diabetes mellitus group compared to the healthy group, and high-density lipoprotein cholesterol levels were found to be lower. After major autohemotherapy, GDF-15 and low-density lipoprotein cholesterol decreased significantly in the type-2 diabetes mellitus group. No change was observed in the healthy group.
As a new treatment strategy, major autohemotherapy reduces GDF-15 levels in type-2 diabetes mellitus and contributes to the therapeutic effects of ozone therapy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1078-6791 |